Patients who have received prior anti-PD1 directed therapy (monoclonal antibody [mAb] or small molecule) are not eligible
Treatment with anti-myeloma monoclonal antibodies within 6 weeks prior first dose.
Treatment with a monoclonal antibody within 30 days prior to Cycle 1, Day 1
Prior use of any monoclonal antibody, radioimmunoconjugate, or antibody-drug conjugate within 4 weeks before first infusion
Prior treatment with a monoclonal antibody or chimeric antigen receptor T cell (CAR-T) infusion for the treatment of AML (CD33 or other target).
Immune therapy (including monoclonal antibody therapy) -6 weeks
At least 6 weeks must have elapsed since prior therapy that includes a monoclonal antibody prior to registration
Prior radiation therapy or chemotherapy within 2 weeks prior cycle 1, day 1, monoclonal antibody therapy within 4 weeks
Receipt of any type of anticancer antibody (including investigational antibody) within 4 weeks before planned first dose of study drug
Monoclonal antibody or antibody-drug conjugate (ADC) therapy within 3 weeks prior to Day 1 of Cycle 1.
Prior treatment against NSCLC with an EGFR monoclonal antibody
?28 days for prior monoclonal antibody used for anticancer therapy with the exception of denosumab.
Prior treatment with a monoclonal antibody or chimeric antigen receptor T cell infusion for the treatment of AML
Any therapeutic antibody within 4 weeks of first dose of study drugs.
No monoclonal antibody within 3 months unless evidence of disease progression
Has received any prior anti-cancer therapy, monoclonal antibody, chemotherapy, or an investigational agent or device before the first dose of study treatment, or has not recovered from AEs due to previously administered agents
Antibody therapy
Patients must not have had chemotherapy, major surgery, monoclonal antibody therapy or experimental therapy within the 21 days prior to the start of ibrutinib administration
Received a monoclonal antibody or immunoglobulin -based agent within 1 year of Screening, or has documented immunogenicity to a prior biologic.
Patients who have received any monoclonal antibody therapy within 4 weeks prior to entering the study
Patients who have received monoclonal anti-cancer antibody within 4 weeks of first dose of study drugs
Chemotherapy =< 21 days prior to first administration of study treatment and/or monoclonal antibody =< 4 weeks prior to first administration of study treatment
Received any prior monoclonal antibody (except an anti-CD20 antibody) within 90 days before the date of study start.
Prior chemotherapy, immunotherapy, radioactive, or biological cancer therapy (including monoclonal antibody [mAb]) within 28 days prior to registration
Prior use of any monoclonal antibody within 3 months of the start of Cycle 1
Subjects who have had treatments with anti-cancer agents including rituximab or obinutuzumab and/or other monoclonal antibody or radioimmunotherapy within 6 weeks before the starting IP treatment.
Participants who are receiving any other investigational agents or have received investigational therapy or any anti-cancer monoclonal antibody (mAB) within 4 weeks prior to the 1st dose of pembrolizumab
Use of other systemic anticancer treatments or agents within the past 2 weeks (4 weeks if the therapy was a monoclonal antibody)
Cytotoxic chemotherapy =< 21 days prior to first administration of study treatment and/or monoclonal antibody =< 4 weeks prior to first administration of study treatment and/or other renal cell carcinoma (RCC)-directed systemic therapy =< 2 weeks prior to first administration of study treatment
Patients who have had prior exposure to immune checkpoint inhibitors are not eligible; please contact principal investigator, William Gradishar at 312-695-4541 for specific questions on potential interactions\r\n* PD-1 monoclonal antibody: pembrolizumab, pidilizumab, MEDI-0680, anti-PD-1 fusion protein AMP-224 (AMP-224), anti-PD-1 checkpoint inhibitor PF-06801591 (PF-06801591), anti-PD-1 monoclonal antibody BGB-A317 (BGB-A317), anti-PD-1 monoclonal antibody PDR001 (PDR001), anti-PD-1 monoclonal antibody REGN2810 (REGN2810), anti-PD-1 monoclonal antibody SHR-1210 (SHR-1210)\r\n* PD-L1 monoclonal antibody: durvalumab, avelumab, anti-PD-L1 monoclonal antibody MDX-1105 (MDX-1105), atezolizumab, zirconium Zr 89-labeled anti-PD-L1 monoclonal antibody MPDL3280A (MPDL3280A)\r\n* CTLA4 monoclonal antibody: tremelimumab, abatacept\r\n* OX40: agonistic anti-OX40 monoclonal antibody MEDI6383 (MEDI6383), agonistic anti-OX40 monoclonal antibody MEDI6469 (MEDI6469), anti-OX40 monoclonal antibody MEDI0562 (MEDI0562), oxelumab, anti-OX40 antibody PF-04518600 (PF-04518600)
Any of the following within 3 weeks prior to initiating study treatment\r\n* Systemic biologic therapy\r\n* Monoclonal antibody\r\n* Chemotherapy\r\n* TSEB \r\n* Phototherapy\r\n* Other investigational therapy
Patients who have received a prior monoclonal antibody =< 28 days prior to study day -14 are not eligible
Major surgery, radiotherapy, chemotherapy, biologic therapy, immunotherapy, experimental therapy within 3 weeks prior to the first dose of the study drugs and/or monoclonal antibody =< 6 weeks prior to first administration of study treatment
Prior systemic use of any immunosuppressive chemotherapy (except low dose methotrexate) and/or monoclonal antibody treatment for CTCL
Known allergic reaction to a prior monoclonal antibody therapy or have any documented Anti-Drug Antibody (ADA) response
Prior therapy with monoclonal antibody (mAb) against CTLA-4
At least 7 days must have elapsed after the last of a biologic agent that is not a monoclonal antibody, to be enrolled on this study
Receipt of the following treatment prior to first dose of BGB-3111: corticosteroids given with anti-neoplastic intent within 7 days, chemotherapy or radiotherapy within 2 weeks, monoclonal antibody within 4 weeks.
Anticancer therapy, monoclonal antibody or major surgery within 4 weeks prior to the first dose of MEDI4736\r\n* Concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptable
Patients must be at least 28 days post cytotoxic chemotherapy, and/or monoclonal antibody therapy (excluding bone-directed therapy), prior to enrollment
Use of other anticancer treatments or agents within the past 4 weeks (6 weeks if the therapy was a monoclonal antibody)
Prior monoclonal antibodies, antibody-drug conjugates, or radioimmunoconjugates within 4 weeks (or 2 weeks if patient experienced disease progression on the prior treatment)
Received any antibody targeting T-cell check point or co-stimulation pathways within 4 weeks, received any other monoclonal antibody within 4 weeks, and all other immunotherapy (tumor vaccine, cytokine, or growth factor) within 2 weeks prior to study treatment.
Prior treatment with a HER3 antibody
Prior treatment with a monoclonal antibody within 30 days of receiving the first dose of study drugs.
Monoclonal antibody within 28 days prior to day 1 of protocol therapy
Any of the following:\r\n* Prior anti-cancer monoclonal antibody (mAb) =< 4 weeks prior to registration
Chemotherapy =< 21 days prior to first administration of study treatment and/or monoclonal antibody =< 6 weeks prior to first administration of study treatment
Previous monoclonal antibody (mAb) or other treatment specifically directed against CD19; history of serious allergy or reaction to any component of the MEDI-551 formulation that would prevent administration
Monoclonal antibody therapy administered within 30 days of the agent prior to apheresis
Other monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, or T-cell or other cell-based therapies: 4 weeks (2 weeks with documented disease progression)
Use of any monoclonal based therapies within 2-4 weeks prior to the first dose of study treatment.
Monoclonal antibody (mAb) for direct anti-neoplastic treatment within 4 weeks
At least 4 weeks from end of monoclonal antibody therapy
Prior monoclonal antibody treatment within 4 weeks before study Day 1
Any therapeutic antibody within 4 weeks of first dose of study drugs.
Monoclonal antibody (ies) At least 28 days
Prior use of any monoclonal antibody, radio-immuno-conjugate or antibody drug conjugate within 4 weeks before study start
Monoclonal antibody therapy within 4 weeks prior to the planned start of study treatment.
Chemotherapy =< 21 days prior to first administration of study treatment and/or monoclonal antibody =< 6 weeks prior to first administration of study treatment
Have received prior treatment with monoclonal antibodies within 6 weeks of first dose of Day 1;
Prior use of any monoclonal antibody or antibody-drug conjugate within 4 weeks before Cycle 1, Day 1
Received prior monoclonal antibody (mAb) within 4 weeks prior to study.
Subjects who have previously received anti-GD2 monoclonal antibodies for biologic therapy or for tumor imaging are eligible unless they have had progressive disease while receiving prior anti-GD2 therapy; subjects who have received autologous marrow infusions or autologous stem cell infusions that were purged using monoclonal antibody linked to beads, but no other form of anti-GD2 monoclonal antibody, are eligible
Subject has received treatment with any monoclonal antibodies within 4 weeks prior to first dose of study therapy
Have received an antibody therapy within 3 weeks
Monoclonal antibody, radioimmunoconjugate, antibody-drug conjugate, chemotherapy, or other investigational anti-cancer agent within 4 weeks prior to study drug
History of severe infusion reactions to monoclonal antibody therapy
Use of investigational agents within 4 weeks prior to study enrollment (within 6 weeks if the treatment was with a long-acting agent such as a monoclonal antibody).
The participant has undergone major surgery or received anti-cancer monoclonal antibody therapy in the 30-days prior to study enrollment.
Has had a prior monoclonal antibody therapy within 2 weeks prior to study Day 1. (Prior anti-HER2 therapy is acceptable).
Patient has had a prior monoclonal antibody for treatment of MCC
Received an anti-CLL monoclonal antibody within 8 weeks prior to the first dose of study drug
A 3-week washout period is required from previous treatments (with the exception of a 12-week washout for antibody-directed or immunoglobulin-based immune therapy, or other monoclonal antibody therapies), unless it is not in the best interest of the patient in the opinion of the investigator. Individual cases should be discussed with the project clinician before enrollment.
Corticosteroid therapy within 3 weeks or immunosuppressive chemotherapy or any antibody-directed or immunoglobulin-based immune therapy (e.g., immunoglobulin replacement, other monoclonal antibody therapies) within 12 weeks of first dose of study drug
monoclonal antibody therapy must be completed at least 6 weeks prior to pre-infusion lymphodepletive chemotherapy
All previous cytotoxic chemotherapy, monoclonal antibody therapy, immune therapy should be washed out 3 weeks before apheresis and must be completed at least 3 weeks prior to pre-infusion lymphodepletive chemotherapy.
Subject has received a monoclonal antibody for anti-neoplastic intent within 8 weeks prior to the first dose of study drug.
Chemotherapy =< 21 days prior to first administration of study treatment and/or monoclonal antibody =< 3 weeks prior to first administration of study treatment
Previously received an EGFR-directed monoclonal antibody within the past 4 weeks.
In the absence of rapidly progressing disease and after discussion with the Principal Investigator (PI), the interval from prior treatment to time of IMGN901 administration will be at least 2 weeks or at least 5 half-lives for cytotoxic/noncytotoxic agents; for prior monoclonal antibody therapy the interval from prior monoclonal antibody treatment to time of IMGN901 administration will be at least 2 weeks; the use of chemotherapeutic or anti-leukemic agents other than hydroxyurea is not permitted during the study with the exception of intrathecal (IT) therapy for patients with controlled central nervous system (CNS) leukemia at the discretion of the PI; hydroxyurea is allowed prior to the initiation of IMGN901 and during the first 3 cycles, either prior to or concomitantly with IMGN901 administration initially to control leukocytosis
Subject has received a monoclonal antibody for anticancer intent within 8 weeks prior to the first dose of study drug.
Monoclonal antibody therapy < 30 days from study enrollment
Monoclonal antibody therapy less than 1 month
Monoclonal antibodies: at least 4 weeks must have elapsed since prior therapy that included a monoclonal antibody
Treatment with chemotherapy or monoclonal antibody within 28 days prior to entering the study
Treatment with chemotherapy or monoclonal antibody during the time of participation in this trial
Prior treatment with any investigational drug, chemotherapy, or monoclonal antibody within the preceding 1 month
Less than four weeks since last monoclonal antibody-containing therapy
Known hypersensitivity to afatinib, monoclonal antibody
Patients who have not yet completed at least 28 days (30 days for prior monoclonal antibody therapy) since receiving other investigational drugs
Prior monoclonal antibody: participants having received prior in vivo monoclonal anti-GD2 antibodies for biologic therapy or for tumor imaging AND experienced a severe allergic reaction while receiving prior anti-GD2 therapy; (Note: participants who have received previous therapy with anti-GD2 monoclonal antibodies are eligible for this study, provided they did not experience a severe allergic reaction with the antibody)
Received the last administration of an anticancer monoclonal antibody, immunotherapy, hormonal therapy, or chemotherapy (except nitrosoureas and mitomycin-C) =< 28 days prior to study registration or who have not recovered from the side effects of such therapy
Systemic anticancer treatment (including investigational agents) less than 3 weeks before the first dose of study treatment (<=4 weeks for antibody-based therapy including unconjugated antibody, antibody-drug conjugate, and bi-specific T-cell engager agents; <=8 weeks for cell-based therapy or anti-tumor vaccine).
At least 14 days must have elapsed since the completion of therapy with a monoclonal antibody
Have received prior treatment with monoclonal antibodies within 6 weeks of first dose of Day 1;
EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Chemotherapy =< 21 days prior to first administration of study treatment and/or monoclonal antibody =< 6 weeks prior to first administration of study treatment
All previous cytotoxic chemotherapy, monoclonal antibody therapy, or immune therapy must be washed out 3 weeks before apheresis and must be completed at least 3 weeks prior to pre-infusion lymphodepletive chemotherapy.
Monoclonal antibody immunotherapies (eg, PD-1, CTLA-4): 6 weeks
History of infusion reactions to monoclonal antibody therapies
History of infusion reactions to panitumumab or other monoclonal antibody therapies
History of infusion reactions monoclonal antibody therapies
Prior chemotherapy, monoclonal antibody or immunotherapy (eg, tumor vaccine, cytokine, or growth factor given to control the cancer) must have been completed at least 4 weeks before study drug administration, and all AEs have either returned to baseline or resolved to Grade 0 or 1
Systemic anticancer treatment (including investigational agents) less than 3 weeks before the first dose of study treatment (<=4 weeks for antibody-based therapy including unconjugated antibody, antibody-drug conjugate, and bi-specific T-cell engager agent; <=8 weeks for cell-based therapy or anti-tumor vaccine).
Known intolerance to CD20 monoclonal antibody therapy
Systemic anticancer treatment including investigational agents or radiotherapy <2 weeks before the first dose of study treatment (<4 weeks for antibody-based therapy including unconjugated antibody, antibody-drug conjugate, and bi-specific T-cell engager agents; <=8 weeks for cell-based therapy or antitumor vaccine) or have not recovered from acute toxic effects from prior chemotherapy and radiotherapy.